The Johnson & Johnson vaccine, manufactured by Hyderabad-based Biological E, is likely to be rolled out by October, multiple media reports claimed on Thursday. The company was earlier aiming to produce 600 million doses of the vaccine.
Earlier in August, Johnson & Johnson’s single-dose COVID-19 vaccine was given Emergency Use Approval (EUA) in India. The Union health minister had said this will further boost India’s collective fight against coronavirus infection. The five vaccines granted emergency use authorisation in India are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna and J&J.
In global efficacy trials, the J&J vaccine was found to be 66 per cent effective overall and 85 per cent effective against severe infections. In the US, it was found to be 72 per cent effective against moderate and severe disease.
If a third wave hits India in the coming months, as many experts have predicted it will, J&J vaccine could be a big boost—the availability of a single-shot vaccine will mean a much higher percentage of the population will be covered in a much shorter period of time. Also, the vaccine is quite easy to store and transport, with a two degree to eight degree temperature requirements.
Can’t entertain plea at behest of political party: SC on plea by CPI(M) against demolition in Shaheen Bagh
NEW DELHI: The Supreme Court Monday refused to entertain a plea filed by CPI(M) again…